Influence of decisions related to business and regulatory considerations on therapeutic development for kidney diseases

Clinical Journal of the American Society of Nephrology

Volumn 7, Issue 7, 2012, Pages 1195-1199

  Dwight McKinney, T ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CAPTOPRIL; CREATININE; IRBESARTAN; LOSARTAN;

ACUTE KIDNEY FAILURE; ALBUMINURIA; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DISEASE COURSE; DRUG APPROVAL; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG INDUSTRY; DRUG LABELING; DRUG MANUFACTURE; DRUG MARKETING; DRUG SAFETY; DRUG SCREENING; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HEMODIALYSIS; HUMAN; HYPERTENSION; IN VITRO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PERITONEAL DIALYSIS; PHARMACODYNAMICS; PHARMACOECONOMICS; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEINURIA; RENAL REPLACEMENT THERAPY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETINOPATHY; SURVIVAL;

EID: 84863733764     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.00270112     Document Type: Article

References (30)

1. r(Captopril) FDA Label. Available at: http://www. accessdata.fda.gov/drugsatfda_docs/label/2011/ 018343s082lbl.pdf. Assessed December 14, 2011
2. r(Losartan) FDA Label. Available at: http://www. accessdata.fda.gov/drugsatfda_docs/label/2011/020386s05. Accessed December 14, 2011
3. r(Irbesartan) FDA Label. Available at: http://www. accessdata.fda.gov/drugsatfda_docs/label/2011/0. Accessed December 14, 2011
4. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD; The Collaborative Study Group: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329: 1456-1462, 1993
5. Brenner BM, Cooper ME, De Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators: Effects of losartan on renal function and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001: 861-869, 2001
6. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde RD, Raz I; Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860, 2001
7. United States Government Accountability Office: United States Government Accountability Office Report to Congressional Requesters. New drug Development: Science, Business, Regulatory, and Intellectual Property Issues Cited as Hampering Drug Development Efforts. GAO-07-49, Washington, DC, US Government Accountability Office, 2006
8. Kaitin KI: Deconstructing the drug development process: The new face of innovation. Clin Pharmacol Ther 87: 356-361, 2010
9. Centers for Disease Control and Prevention: National Chronic Kidney Disease Fact Sheet: General Information and National Estimates on Chronic Kidney Disease in the United States, 2010, Atlanta, GA, US Department of Health and Human Services, Centers for Disease Control and Prevention, 2010
10. US Renal Data System: USRDS 2011 Annual Data Report: Atlas of Chronic KidneyDisease and End-Stage RenalDisease in theUnited States, National Institutes of Health, National Institute of Diabetes andDigestive and KidneyDiseases, Bethesda, MD, 2011. Available at: http://www.usrds.org/adr.htm. Accessed November, 15, 2011
11. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, WaldronW, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, ChoH, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA, Edwards BK, editors: SEER Cancer Statistics Review, 1975-2008, National Cancer Institute. Available at: http://seer.cancer.gov/ csr/1975_2008/. Accessed December 30, 2011
12. DiMasi JA, Feldman L, Seckler A, Wilson A: Trends in risks associated with new drug development: Success rates for investigational drugs. Clin Pharmacol Ther 87: 272-277, 2010
13. PHRMA: Drug Discovery and Development. Available at: http:// www.phrma.org/research/drug-discovery-development. Accessed December 14, 2011
14. Collier R: Drug development cost estimates hard to swallow. CMAJ 180: 279-280, 2009
15. Bodrogi J, Kaló Z: Principles of pharmacoeconomics and their impact on strategic imperatives of pharmaceutical research and development. Br J Pharmacol 159: 1367-1373, 2010
16. Dunn MK: Timing of patent filing andmarket exclusivity. Nat Rev Drug Discov 10: 487-488, 2011
17. Wood AJJ: A proposal for radical changes in the drug-approval process. N Engl J Med 355: 618-623, 2006
18. Kaitin KI: 21st century innovation: Academic-industry partnerships are increasingly important in biopharmaceutical innovation. Pharm Technol 35: 32, 2011
19. Amur S, Frueh FW, Lesko LJ, Huang SM: Integration and use of biomarkers in drug development, regulation and clinical practice: A US regulatory perspective. Biomark Med 2: 305-311, 2008
20. IOM (Institute of Medicine): Accelerating the Development of Biomarkers for Drug Safety: Workshop Summary, Washington, DC, The National Academies Press, 2009
21. Bakris GL: Slowing nephropathy progression: Focus on proteinuria reduction. Clin J Am Soc Nephrol 3[Suppl 1]: S3-S10, 2008
22. Stevens LA, Greene T, Levey AS: Surrogate end points for clinical trials of kidney disease progression. Clin J Am Soc Nephrol 1: 874-884, 2006
23. National Institutes of Health: NIH Clinical Trials. Available at: http://clinicaltrials.gov. Accessed January 3, 2012
24. Tesch GH: Review: Serum and urine biomarkers of kidney disease: A pathophysiological perspective. Nephrology (Carlton) 15: 609-616, 2010
25. Fassett RG, Venuthurupalli SK, Gobe GC, Coombes JS, Cooper MA, Hoy WE: Biomarkers in chronic kidney disease: A review. Kidney Int 80: 806-821, 2011
26. Fast Track, Accelerated Approval and Priority Review Accelerating Availability of New Drugs for Patients with Serious Diseases. Available at: http://www.fda.gov/forconsumers/byaudience/ forpatientadvocates/speedingaccesstoimportantnewtherapies/ ucm128291.htm. Accessed December 30, 2011
27. Levey AS, Stevens LA: Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: More accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. Am J Kidney Dis 55: 622-627, 2010
28. Köttgen A, Pattaro C, Böger CA, Fuchsberger C, OldenM, Glazer NL, Parsa A, Gao X, Yang Q, Smith AV, O'Connell JR, Li M, Schmidt H, Tanaka T, Isaacs A, Ketkar S, Hwang SJ, Johnson AD, Dehghan A, Teumer A, Paré G, Atkinson EJ, Zeller T, Lohman K, Cornelis MC, Probst-Hensch NM, Kronenberg F, Tönjes A, Hayward C, Aspelund T, Eiriksdottir G, Launer LJ, Harris TB, Rampersaud E, Mitchell BD, ArkingDE, Boerwinkle E, Struchalin M, Cavalieri M, Singleton A, Giallauria F, Metter J, de Boer IH, Haritunians T, Lumley T, Siscovick D, Psaty BM, Zillikens MC, Oostra BA, Feitosa M, Province M, de Andrade M, Turner ST, Schillert A, Ziegler A, Wild PS, Schnabel RB, Wilde S, Munzel TF, Leak TS, Illig T, Klopp N, Meisinger C, Wichmann HE, KoenigW, Zgaga L, Zemunik T, Kolcic I, Minelli C, Hu FB, Johansson A, Igl W, Zaboli G, Wild SH, Wright AF, Campbell H, Ellinghaus D, Schreiber S, Aulchenko YS, Felix JF, Rivadeneira F, Uitterlinden AG, Hofman A, ImbodenM, NitschD, Brandstätter A, Kollerits B, Kedenko L, Mägi R, Stumvoll M, Kovacs P, BobanM, Campbell S, Endlich K, Völzke H, Kroemer HK, Nauck M, Völker U, Polasek O, Vitart V, Badola S, Parker AN, Ridker PM, Kardia SL, Blankenberg S, Liu Y, Curhan GC, Franke A, Rochat T, Paulweber B, Prokopenko I, WangW, Gudnason V, Shuldiner AR, Coresh J, Schmidt R, Ferrucci L, Shlipak MG, van Duijn CM, Borecki I, Krämer BK, Rudan I, Gyllensten U, Wilson JF, Witteman JC, Pramstaller PP, Rettig R, Hastie N, Chasman DI, Kao WH, Heid IM, Fox CS: New loci associated with kidney function and chronic kidney disease. Nat Genet 42: 376-384, 2010
29. Chronic Kidney Disease Biomarker Discovery and Validation Consortium (U01). Available at: http://grants.nih.gov/grants/ guide/rfa-files/RFA-DK-08-015.html. Accessed January 3, 2012
30. Reducing the Impact of Chronic Kidney Disease: Opportunities for Randomized Clinical Trials. Available at: http://www3.niddk. nih.gov/fund/other/ckdclintrials2011/agenda.htm. Accessed March 8, 2012